Document Detail


Systemic effects of medications used to treat glaucoma.
MedLine Citation:
PMID:  1967209     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Medications used to treat glaucoma can have clinically important systemic effects in some patients; these effects may not be recognized in elderly patients who have chronic medical problems and who are taking several systemic medications. Beta-blocking ophthalmic agents are generally safe, but can be absorbed systemically to induce bronchospasm, worsen heart block, decompensate congestive heart failure, or create central nervous system effects in some patients. Reports of adverse systemic effects from miotics, such as pilocarpine, are rare, although cardiovascular decompensation has been seen in patients with acute angle closure who were given excessive doses before surgery. Topical sympathomimetic agents such as epinephrine may increase ventricular extrasystoles and have, on occasion, caused severe hypertensive reactions. Nearly 50% of patients taking carbonic anhydrase inhibitors must discontinue their use because of various adverse constitutional and central nervous system symptoms. Although these drugs are not usually part of internal medicine regimens, they can produce adverse effects that mimic primary disease in nonocular organ systems.
Authors:
D E Everitt; J Avorn
Related Documents :
1460679 - Analysis of prehospital delay among inner-city patients with symptoms of myocardial inf...
20577129 - Increased pulse wave velocity and not reduced ejection fraction is associated with impa...
10073869 - Effect of beta-adrenergic blocker therapy on the circadian rhythm of heart rate variabi...
3677499 - The role of active myocarditis in the development of heart failure in chronic chagas' d...
24331009 - Relationship of body mass index and waist-to-hip ratio with fibrinolytic activity measu...
16756409 - Expressed emotion, adaptation, and patient survival among couples coping with chronic h...
6872269 - Skin thickness in patients with acromegaly and cushing's syndrome and response to treat...
3400819 - Does intracranial dye study contribute to evaluation of carotid artery disease?
6440179 - Prolactin, amitriptyline, and recovery from depression.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Annals of internal medicine     Volume:  112     ISSN:  0003-4819     ISO Abbreviation:  Ann. Intern. Med.     Publication Date:  1990 Jan 
Date Detail:
Created Date:  1990-02-06     Completed Date:  1990-02-06     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0372351     Medline TA:  Ann Intern Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  120-5     Citation Subset:  AIM; IM    
Affiliation:
Beth Israel Hospital, Brockton-West Roxbury Veterans Affairs Medical Center.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic beta-Antagonists / adverse effects
Brain / drug effects
Carbonic Anhydrase Inhibitors / adverse effects
Glaucoma / drug therapy*
Hemodynamics / drug effects
Humans
Miotics / adverse effects
Respiration Disorders / chemically induced
Sympathomimetics / adverse effects
Grant Support
ID/Acronym/Agency:
EY-07715/EY/NEI NIH HHS; FD-0015D/FD/FDA HHS
Chemical
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Carbonic Anhydrase Inhibitors; 0/Miotics; 0/Sympathomimetics

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Huntington disease in Finland: linkage disequilibrium of chromosome 4 RFLP haplotypes and exclusion ...
Next Document:  Pharmacologic and nutritional treatment of mild hypertension: changes in cardiovascular risk status.